220 related articles for article (PubMed ID: 35227948)
1. OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization.
Sacconi R; Forte P; Tombolini B; Grosso D; Fantaguzzi F; Pina A; Querques L; Bandello F; Querques G
Ophthalmol Retina; 2022 Jul; 6(7):586-594. PubMed ID: 35227948
[TBL] [Abstract][Full Text] [Related]
2. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
3. Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.
Hosseini H; Rabina G; Pettenkofer M; Au A; Chehaibou I; Heilweil G; Weiner AJ; Ip M; Loewenstein A; Schwartz SD
Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1153-1160. PubMed ID: 33245430
[TBL] [Abstract][Full Text] [Related]
4. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
5. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Rofagha S; Bhisitkul RB; Boyer DS; Sadda SR; Zhang K;
Ophthalmology; 2013 Nov; 120(11):2292-9. PubMed ID: 23642856
[TBL] [Abstract][Full Text] [Related]
6. Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients.
Kim KT; Chae JB; Lee S; Seo EJ; Kim DY
BMC Ophthalmol; 2021 Aug; 21(1):294. PubMed ID: 34376158
[TBL] [Abstract][Full Text] [Related]
7. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
8. Can objective parameters in optical coherence tomography be useful markers in the treatment and follow-up of type 1 and type 2 macular neovascularizations related to neovascular age-related macular degeneration?
Özen O; Koçak Altıntaş AG
Int Ophthalmol; 2024 Mar; 44(1):134. PubMed ID: 38483688
[TBL] [Abstract][Full Text] [Related]
9. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes.
Toto L; Viggiano P; Quarta A; Grassi M; De Nicola C; Aloia R; D'Aloisio R; Boscia G; Boscia F; Porreca A; Di Nicola M; Savastano MC; Mastropasqua R
Ophthalmic Res; 2024; 67(1):282-291. PubMed ID: 38621369
[TBL] [Abstract][Full Text] [Related]
10. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.
Schmidt-Erfurth U; Bogunovic H; Sadeghipour A; Schlegl T; Langs G; Gerendas BS; Osborne A; Waldstein SM
Ophthalmol Retina; 2018 Jan; 2(1):24-30. PubMed ID: 31047298
[TBL] [Abstract][Full Text] [Related]
11. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
[TBL] [Abstract][Full Text] [Related]
12. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
[TBL] [Abstract][Full Text] [Related]
13. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
[TBL] [Abstract][Full Text] [Related]
14. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
15. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
[TBL] [Abstract][Full Text] [Related]
16. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
17. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
18. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
19. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
[TBL] [Abstract][Full Text] [Related]
20. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
